Exclusive Summary

• The sustained-release form boasts significant advantages over conventional tablets, including a lower dosing frequency (12-hour efficacy) and reduced gastrointestinal irritation, perfectly matching formulation-upgrade demands in emerging markets.
• Firmly listed on the WHO Model List of Essential Medicines, Ibuprofen remains the rigorous first-line gold standard in the multibillion-dollar analgesic/antipyretic sector, guaranteeing an immovable rigid global demand.
• Leveraging China's absolute global dominance in Ibuprofen API production, this finished product enjoys a tremendous vertically integrated cost advantage, ensuring highly lucrative profit margins for exclusive regional distributors.
• Capable of supplying premium formulations compliant with modern USP/BP/EP standards alongside full CTD format dossiers, robustly empowering overseas partners for rapid localized regulatory registration and seamless distribution.